Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors.
Intravenous ribavirin was given to nine patients who had developed severe adenovirus-induced hemorrhagic cystitis (AD-HC) which was resistant to conventional therapy or where there was involvement of other organs after allogeneic BMT. Three patients recovered completely from AD-HC, two of whom had been resistant to vidarabine. All three had received sibling BMTs (2 HLA matched, 1 HLA mismatched). Five patients who received BMTs from related (2 HLA mismatched) or unrelated (1 HLA matched, 2 HLA mismatched) showed an improvement in symptoms but had recurrent AD-HC after discontinuation of ribavirin. Improvement in clinical symptoms and termination of virus excretion were well correlated. The last patient who received a mismatched unrelated BMT died during ribavirin therapy. Ribavirin was notably more effective among patients receiving BMTs from siblings in contrast to patients receiving BMTs from alternative donors (<0.05). One patient experienced severe pancytopenia during the second treatment with ribavirin after HC recurrence and recovered after ceasing ribavirin. Thus, ribavirin seems to be very effective for severe AD-HC for some recipients who receive transplants from a genetically close donor. Bone Marrow Transplantation (2000) 25, 545-548.
Miyamura
K
K
First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Hamaguchi
M
M
Taji
H
H
Kanie
T
T
Kohno
A
A
Tanimoto
M
M
Saito
H
H
Kojima
S
S
Matsuyama
T
T
Kitaori
K
K
Nagafuji
K
K
Sato
T
T
Kodera
Y
Y
D000257:Adenoviridae Infections / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use* / Q000633:toxicity; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D003556:Cystitis / Q000188:drug therapy* / Q000821:virology*; D005260:Female; D005334:Fever; D006680:HLA Antigens; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D006470:Hemorrhage / Q000188:drug therapy / Q000382:microbiology; D006648:Histocompatibility / Q000276:immunology*; D006801:Humans; D008297:Male; D009679:Nuclear Family; D010198:Pancytopenia / Q000139:chemically induced; D012254:Ribavirin / Q000008:administration & dosage* / Q000633:toxicity; D015996:Survival Rate; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000009:adverse effects
D000998:Antiviral Agents; D006680:HLA Antigens; D012254:Ribavirin